A profoundly important natural hormone — sold for a narrow, single-investigator gray-market niche. This entry is a study in contrast. Three threads: (1) VIP is a real endogenous neuropeptide with huge, well-established physiology — it's literally a master regulator of the brain's circadian clock; (2
VIP is a 28-amino-acid endogenous neuropeptide with broad, well-established physiology — it's a potent vasodilator and bronchodilator, a strong anti-inflammatory/immune regulator, and, strikingly, a master neurotransmitter of the brain's circadian clock (the SCN uses VIP to keep the body on solar time; mice without VIP lose their rhythms). Given all that, its gray-market life is surprisingly narrow: it's used mainly as a compounded nasal spray in the "CIRS / mold-illness" protocol of one physician, Ryan Shoemaker, as the final "capstone" step after upstream treatments — on the theory that biotoxin illness depletes regulatory neuropeptides. The catch: almost all the human evidence (an open-label trial of 20 patients, a 15-patient RNA-Seq study, a brain-volume study) comes from Shoemaker's own group, is small and open-label, isn't independently replicated, and addresses a diagnosis (CIRS) that mainstream medicine doesn't broadly recognise. Meanwhile the FDA has moved to pull VIP from the compounding list, and the serious drug-development action is elsewhere (the analog aviptadil in ARDS/COVID). Honest read: a genuinely important hormone whose headline gray-market use is thinly evidenced and single-sourced — big biology, small and shaky proof for the thing it's sold for.
not an approved consumer product; investigational. Not a cosmetic.
not an approved drug for CIRS or general use; historically available as a compounded nasal spray (503A) — but the FDA has moved to remove VIP from the compoundable list, clouding that route. The analog aviptadil has been investigational (ARDS/COVID), not generally approved.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (watch: FDA compounding status, and whether any independent (non-Shoemaker) controlled trial of intranasal VIP in CIRS or inflammatory disease appears — that would be decisive).
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.